Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023)

Rocket Pharmaceuticals' Long-Term Investments history spans 3 years, with the latest figure at $34.3 million for Q4 2023.

  • For Q4 2023, Long-Term Investments fell 20.7% year-over-year to $34.3 million; the TTM value through Dec 2023 reached $34.3 million, down 20.7%, while the annual FY2023 figure was $34.3 million, 20.7% down from the prior year.
  • Long-Term Investments for Q4 2023 was $34.3 million at Rocket Pharmaceuticals, up from $29.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $43.3 million in Q4 2022 and bottomed at $29.0 million in Q1 2023.